Outcomes of first-line treatment of non-Hodgkin and Hodgkin lymphomas in real-world practice – an analysis of patients treated at the Department of Haematooncology, University Hospital Ostrava, from 2013 to 2022
Authors:
B. Šušolová 1; J. Ďuraš 1,2; I. Kováčová 1; K. Hradská 1,2; M. Kaščák 1; M. Navrátil 1,2; M. Lachnit 1; R. Hájek 1,2
Published in:
Transfuze Hematol. dnes,31, 2025, No. 2, p. 81-96.
Category:
Original Papers
doi:
https://doi.org/10.48095/cctahd2025prolekare.cz8
Overview
Lymphomas are a heterogeneous group of lymphoid tissue tumours that differ in histopathological and immunohistochemical features, clinical presentations, prognosis, and treatment strategies. While a large body of data from clinical trials in specific populations is available, few studies have been published regarding outcomes in unselected patient groups from everyday clinical practice. This retrospective analysis presents the results of first-line treatment in 668 patients with non-Hodgkin lymphoma (NHL) and 142 patients with Hodgkin lymphoma (HL) treated between 2013 and 2022 at the Department of Haematooncology, University Hospital Ostrava. The study primarily focuses on key clinical evaluation parameters, including treatment response (TR), progression-free survival (PFS), and overall survival (OS) in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and HL. In a subanalysis, we further evaluated the impact of previously published known risk factors on treatment outcomes. In the DLBCL group, 82% (221/274) of patients were treated with the R-CHOP/“R-CHOP-like” regimen, with 80% (177/221) achieving complete remission (CR). The median PFS and OS were 122 months, with 5-year PFS and OS rates of 61% and 66%, respectively. Low IPI risk and, to some extent, the GCB (germinal centre B-cell-like) immunophenotype were associated with favourable PFS and OS. Of the 134 patients with FL, 60% (80/134) received first-line chemotherapy in combination with anti-CD20 monoclonal antibody, achieving an overall response rate (ORR) of 95% (76/80) and CR in 76% (62/80). No median PFS or OS was reached for this group, but the 5-year PFS and OS rates were 63% and 86%, respectively. Localised disease at diagnosis and low FLIPI risk were associated with a trend towards better survival. Of the 142 HL patients, 96% (136/142) had classical HL (cHL). In the cHL group, the median PFS and OS were not reached, but the 5-year PFS and OS were 75% and 86%, respectively. In the GHSG subgroups, the 5-year PFS and OS were 94% and 100% in early-stage disease, 84% and 90% in intermediate-stage disease, and 68% and 81% in advanced-stage disease. The observed treatment outcomes for lymphoma patients between 2013 and 2022, using standard treatment protocols, are generally comparable to the results of clinical trials and analyses by other authors from routine clinical practice.
Keywords:
Hodgkin lymphoma – Prognosis – overall survival – Diffuse large B-cell lymphoma – progression-free survival – follicular lymphoma
Sources
1. Chu Y, Liu Y, Fang X, et al. The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends. Front Oncol. 2023; 13: 1059914. doi: 10.3389/fonc.2023.1059914.
2. Lopez CA. Non-Hodgkin Lymphoma (NHL). Online. In: Leukemia and lymphoma society. Dostupné z: https: //www.lls.org/lymphoma/ non-hodgkin-lymphoma
3. Alaggio R, Amador C, Anagnostopoulos I, et al. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms”. Leukemia. 2022; 36 (7): 1720–1748. Leukemia. 2023; 37 (9): 1944–1951. doi: 10.1038/s41375-023- 01962-5.
4. Vinjamaram S. Non-Hodgkin Lymphoma (NHL). Online. In: Medscape. 28.5.2024. Dostupné z: https: //emedicine.medscape.com/article/ 203399-overview?form=fpf#a1.
5. Krejčí D, Mužík J, Dušek L. Novotvary 2019-2021 ČR. Online. In: Ústav zdravotnických informací a statistiky ČR. Dokument ve formátu PDF. Dostupné z: https: //www.uzis.cz/res/f/008447/novotvary2019-2021.pdf.
6. The WHO Classification of Tumours Editorial Board, ed. Haematolymphoid Tumours: Who Classification of Tumours. 5th ed. International Agency for Research on Cancer; 2024.
7. Kaseb H, Babiker HM. Hodgkin Lymphoma. In: StatPearls. StatPearls Publishing; 2024. Accessed November 20, 2024. http: //www.ncbi.nlm.nih.gov/books/NBK499969/.
8. Kořen J, Trněný M. [Hodgkin’s lymhoma – the treatment aproaches development and current trends]. Klin Onkol. 2015; 28 (Suppl 3): 3S87–3S94. doi: 10.14735/amko20153s87.
9. Organisation mondiale de la santé, Centre international de recherche sur le cancer, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. International agency for research on cancer; 2008.
10. Weltgesundheitsorganisation. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition. (Swerdlow SH, Campo E, Harris NL, et al., eds.). International Agency for Research on Cancer; 2017.
11. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32 (27): 3059–3068. doi: 10.1200/JCO.2013.54.8800.
12. Belada D, Trněný M. Diagnostické a léčebné postupy u nemocných s maligními lymfomy. Třinácté (10. tištěné) vydání. HK Credit, s. r. o.; 2023.
13. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997; 15 (3): 1110–1117. doi: 10.1200/JCO.1997.15.3.1110.
14. André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017; 35 (16): 1786–1794. doi: 10.1200/JCO.2016.68.6394.
15. Borchmann P, Plütschow A, Kobe C, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22 (2): 223–234. doi: 10.1016/S1470-2045 (20) 30601-X.
16. Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet Lond Engl. 2017; 390 (10114): 2790–2802. doi: 10.1016/S0140-6736 (17) 32134-7.
17. Program R, Core Team R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria.
18. cdc. Centers for Disease Control and Prevention. May 29, 2024. https: //www.cdc.gov/cancer/uscs/about/data-briefs/no30-hematologic-incidence-surv-prev.htm.
19. What is diffuse large B-cell lymphoma (DLBCL) ? Online. In: Blood cancer UK. Dostupné z: https: //bloodcancer.org.uk/understanding-blood-cancer/lymphoma/diffuse-large-b-cell-lymphoma/what-is-dlbcl/.
20. Huang J, Pang WS, Lok V, et al. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. J Hematol Oncol. 2022; 15 (1): 57. doi: 10.1186/s13045-022- 01281-9.
21. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010; 116 (12): 2040–2045. doi: 10.1182/blood-2010-03-276246.
22. Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7 (5): 379–391. doi: 10.1016/S1470-2045 (06) 70664-7.
23. Sehn LH, Salles G. Diffuse large B-cell lymphoma. Longo DL, ed. N Engl J Med. 2021; 384 (9): 842–858. doi: 10.1056/NEJMra20 27612.
24. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology. 2011; 2011 (1): 498–505. doi: 10.1182/asheducation- 2011.1.498.
25. Fabbri N, Mussetti A, Sureda A. Second-line treatment of diffuse large B‐cell lymphoma: Evolution of options. Semin Hematol. 2023; 60 (5): 305–312. doi: 10.1053/j.semin hematol.2023.12.001.
26. Harrysson S, Eloranta S, Ekberg S, et al. Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021; 11 (1): 9. doi: 10.1038/s41408-020-00403-1.
27. Borchmann P, Heger JM, Mahlich J, Papadimitrious MS, Riou S, Werner B. Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database. J Cancer Res Clin Oncol. 2023; 149 (10): 7091–7101. doi: 10.1007/s00432-023-04660-y.
28. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007; 109 (5): 1857–1861. doi: 10.1182/blood- 2006-08-038257.
29. Horvat M, Zadnik V, Južnič Šetina T, et al. Diffuse large B-cell lymphoma: 10 years’ real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone. Oncol Lett. 2018; 15 (3): 3602–3609. doi: 10.3892/ol.2018.7774.
30. Huang H, Fan L, Fu D, Lin Q, Shen J. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center. Ann Palliat Med. 2020; 9 (4): 1442–1452. doi: 10.21037/ apm-19-589.
31. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403 (6769): 503–511. doi: 10.1038/350 00501.
32. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346 (25): 1937–1947. doi: 10.1056/NEJMoa012914.
33. Fu K, Weisenburger DD, Choi WWL, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008; 26 (28): 4587–4594. doi: 10.1200/JCO.2007.15.9277.
34. Robinson SD, Gabriel J, Webb A, et al. Immunohistochemical prognostication in diffuse large B-cell lymphoma: a single center 6-year retrospective analysis. Leuk Lymphoma. 2015; 56 (10): 2975–2977. doi: 10.3109/10428194.2015.1011158.
35. Benesova K, Forsterova K, Votavova H, et al. The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Neoplasma. 2012; 60 (01): 68–73. doi: 10.4149/neo_2013_010.
36. Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood. 2010; 116 (23): 4916–4925. doi: 10.1182/ blood-2010-03-276766.
37. Vodicka P, Masar M, Klanova M, et al. Diagnosis to treatment interval is the most significant prognostic factor compared to symptoms to treatment as well as to contact to treatment intervals in DLBCL patients. Blood. 2023; 142 (Suppl 1): 4510–4510. doi: 10.1182/blood-2023-186467.
38. Maurer MJ, Ghesquières H, Link BK, et al. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol. 2018; 36 (16): 1603–1610. doi: 10.1200/JCO.2017.76.5198.
39. Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32 (3): 298–308. doi: 10.1016/j.annonc.2020.11.008.
40. Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN Guidelines® insights: B-cell lymphomas, version 6.2023: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2023; 21 (11): 1118–1131. doi: 10.6004/jnccn. 2023.0057.
41. Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014; 123 (19): 2944–2952. doi: 10.1182/blood- 2013-11-531327.
42. Casulo C. Response-adapted therapy in follicular lymphoma: at the threshold of a precision approach. J Clin Oncol. 2022; 40 (7): 698–701. doi: 10.1200/JCO.21.02477.
43. Gospodarowicz M. Radiotherapy in non-Hodgkin lymphomas. Ann Oncol. 2008; 19 (Suppl 4): iv47–iv50. doi: 10.1093/annonc/mdn195.
44. Tsang RW, Gospodarowicz MK. Low-grade non-hodgkin lymphomas. Semin Radiat Oncol. 2007; 17 (3): 198–205. doi: 10.1016/j.semradonc. 2007.02.006.
45. Townsend W, Buske C, Cartron G, et al. EP1170 Sustained clinical benefit of obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: updated results from the GALLIUM study. EHA25 Virtual Congress, 2020 Jun 12. Presented at: https: //library.ehaweb.org/eha/2020/eha25th/293659/william.townsend.sustained.clinical.benefit.of.obinutuzumab.plus.chemotherapy.html.
46. Mondello P, Steiner N, Willenbacher W, et al. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3A: evidence from a multicenter, retrospective study. The Oncologist. 2018; 23 (4): 454–460. doi: 10.1634/the oncologist.2017-0037.
47. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. The Lancet. 2013; 381 (9873): 1203–1210. doi: 10.1016/ S0140-6736 (12) 61763-2.
48. Baron MK, Anto E, Esther J, Pappas LM, Shah H. Real world outcomes in patients with follicular lymphoma treated with RCHOP vs BR. J Clin Oncol. 2024; 42 (16_suppl): e19038–e19038. doi: 10.1200/JCO.2024.42.16_suppl.e19038.
49. Suleman A, Aktar SJ, Ante Z, et al. Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario. Br J Haematol. 2023; 202 (6): 1104–1118. doi: 10.1111/bjh. 18972.
50. Jurinovic V, Kridel R, Staiger AM, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016; 128 (8): 1112–1120. doi: 10.1182/blood-2016-05-717355.
51. Zheng W, Liu M, Guan L, Wang S. Outcomes of the transformation of follicular lymphoma to diffuse large B‐cell lymphoma in the rituximab era: A population‐based study. Cancer Med. 2024; 13 (8): e7120. doi: 10.1002/cam4.7120.
52. Wagner-Johnston ND, Link BK, Byrtek M, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015; 126 (7): 851–857. doi: 10.1182/blood-2015- 01-621375.
53. Vaughn JL, Epperla N. Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort study. Biomark Res. 2023; 11 (1): 84. doi: 10.1186/s40364-023-00525-1.
54. Facts and Statistics Overview. Online. In: Leukemia and lymphoma society. Dostupné z: https: //www.lls.org/facts-and-statistics/facts-and-statistics-overview#Hodgkin%20 (HL) %20and%20Non-Hodgkin%20 (NHL) %20Lymphoma.
55. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010; 363 (7): 640–652. doi: 10.1056/NEJMoa10 00067.
56. Fuchs M, Goergen H, Kobe C, et al. Positron emission tomography–guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol. 2019; 37 (31): 2835–2845. doi: 10.1200/JCO.19.00964.
57. André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017; 35 (16): 1786–1794. doi: 10.1200/JCO.2016.68.6394.
58. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet Lond Engl. 2012; 379 (9828): 1791–1799. doi: 10.1016/S0140-6736 (11) 61940-5.
59. Kreissl S, Goergen H, Buehnen I, et al. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021; 8 (6): e398–e409. doi: 10.1016/S2352-3026 (21) 00101-0.
60. Bröckelmann PJ, Müller H, Gillessen S, et al. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. Leukemia. 2022; 36 (3): 772–780. doi: 10.1038/s41375-021-01442-8.
PODÍL AUTORŮ NA RUKOPISU
BŠ – příprava rukopisu, organizace sběru dat, kontrola dat
JĎ – organizace sběru dat, připomínkování rukopisu, konečná kontrola rukopisu
IK – statistické zpracování dat
KH, MN, MK, ML – organizace sběru dat, připomínkování rukopisu
RH – konečná kontrola rukopisu
PROHLÁŠENÍ O KONFLIKTU ZÁJMŮ
Autoři práce prohlašují, že v souvislosti s tématem, vznikem a publikací tohoto článku nejsou ve střetu zájmů a vznik ani publikace článku nebyly podpořeny žádnou farmaceutickou firmou.
Do redakce doručeno dne: 21. 11. 2024.
Přijato po recenzi dne: 4. 3. 2025.
MUDr. Barbora Šušolová
Klinika hematoonkologie
FN Ostrava
17. listopadu 1790/5
708 00 Ostrava
e-mail: barbora.susolova@fno.cz
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2025 Issue 2
Most read in this issue
- Interdisciplinary recommendations for thrombophilia testing
- Cardiovascular complications in multiple myeloma
- Automated digital cytomorphology increases the reliability of bone marrow diagnostics
- Outcomes of first-line treatment of non-Hodgkin and Hodgkin lymphomas in real-world practice – an analysis of patients treated at the Department of Haematooncology, University Hospital Ostrava, from 2013 to 2022